The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021 […]
16 predictions for stem cells & regenerative medicine in 2022 Read More »
The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current
Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
I’d say the paper of the week is on how PRC2 mediated H3K27me3 can in some sense replace elements of DNA methylation to repress. Very cool. Here it is: Sex-specific chromatin remodelling safeguards transcription in germ cells, Nature. Weird stuff In a merger of opposites, City of Hope to buy Cancer Treatment Centers of America
Weekly reads: PRC2, 2 weird bits of news, pubs, COVID stem cell hype Read More »
One of the core problems in the world of unproven stem cell clinics is something called therapeutic misconception. I’ll talk more about that in a minute, but first, let me tell you what brought this to mind now. Surprisingly, the story starts at Duke University. A Duke cell therapy team and the biotech Cryo-Cell have big
Therapeutic misconception & the planned Duke Cryo-Cell cord clinic Read More »
Clade Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the
Clade Therapeutics pursues universal cells for cancer therapy Read More »
Occasionally a reader of The Niche will ask me about stem cell therapy for hair loss and getting a stem cell hair transplant. I’m interested in this research because I’m fascinated by stem cells. Admittedly I don’t have as much hair as I used to so that’s sometimes on my mind too. So where do
Review of stem cell hair transplant for baldness Read More »
Any day now we should get the verdict from the judge in the big stem cell clinic case here in California against Cell Surgical Network, et al. It seems that the FDA is waiting on this verdict before taking some major actions. If the judge rules against the agency it could throw the area into
Weekly stem cell reads: pending FDA verdict, blood vessels, RA Read More »
It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This
Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »
When I first learned about the multi-$10 million cord cell clinic deal between Duke and Cryo-Cell I couldn’t believe what I was reading. Duke’s involved in this? The problem: marketing unproven cells for kids Yes, this wasn’t some stem cell clinic operating out of a strip mall seeking to make big money off of injecting
Vice tackles dicey Cryo-Cell Duke mega-million peds clinic plan Read More »